WestEnd Advisors LLC Raises Holdings in Thermo Fisher Scientific Inc. $TMO

WestEnd Advisors LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.2% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 88,193 shares of the medical research company’s stock after purchasing an additional 2,701 shares during the period. WestEnd Advisors LLC’s holdings in Thermo Fisher Scientific were worth $42,777,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. TIAA Trust National Association grew its holdings in shares of Thermo Fisher Scientific by 10.5% during the second quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock worth $50,256,000 after buying an additional 11,817 shares in the last quarter. Lombard Odier Asset Management Switzerland SA boosted its position in Thermo Fisher Scientific by 8.4% during the second quarter. Lombard Odier Asset Management Switzerland SA now owns 14,490 shares of the medical research company’s stock worth $5,875,000 after acquiring an additional 1,128 shares during the last quarter. Caledonia Investments PLC grew its stake in Thermo Fisher Scientific by 11.5% in the 2nd quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after acquiring an additional 11,500 shares during the period. Weaver Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth $506,000. Finally, Heritage Investors Management Corp grew its position in shares of Thermo Fisher Scientific by 9.6% in the second quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock valued at $22,944,000 after purchasing an additional 4,971 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on TMO shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Cowen reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Wells Fargo & Company boosted their price objective on shares of Thermo Fisher Scientific from $635.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, October 14th. Finally, KeyCorp upgraded Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a research note on Sunday, December 7th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $616.60.

Insider Activity

In related news, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the completion of the sale, the vice president directly owned 14,145 shares of the company’s stock, valued at $8,085,564.90. The trade was a 41.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Michel Lagarde sold 32,000 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total value of $18,668,480.00. Following the transaction, the chief operating officer owned 65,480 shares in the company, valued at $38,200,377.20. This trade represents a 32.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 149,271 shares of company stock worth $86,507,282 over the last ninety days. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $592.19 on Monday. The firm has a market capitalization of $222.49 billion, a PE ratio of 34.21, a price-to-earnings-growth ratio of 3.90 and a beta of 0.91. The stock’s 50 day moving average price is $575.98 and its 200 day moving average price is $510.56. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the prior year, the firm earned $5.28 earnings per share. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.